Fatty liver and the metabolic syndrome
- 1 March 2007
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Gastroenterology
- Vol. 23 (2), 193-198
- https://doi.org/10.1097/mog.0b013e32801421a9
Abstract
Nonalcoholic fatty liver disease and its subset nonalcoholic steatohepatitis represent the liver manifestations of insulin resistance. This review briefly summarizes advances in our understanding of the pathogenesis of nonalcoholic fatty liver disease and its prevalence, natural history and treatment. The recognition of the role the renin-angiotensin system in promoting insulin resistance is worth noting because of available drugs. Endoplasmic reticulum stress has also become a recent target of investigation because endoplasmic reticulum stress is common in obesity, diabetes and various forms of liver disease including nonalcoholic fatty liver disease. Endoplasmic reticulum stress may be responsible for activation of c-Jun kinase, a process that may cause the hepatocellular injury in nonalcoholic steatohepatitis. Progress has also been made in estimating the prevalence of nonalcoholic fatty liver disease in adults and children. Patients enrolled in the Dallas Heart Study were found to have a 33% prevalence of nonalcoholic fatty liver disease and children dying of accidental deaths in San Diego were found to have a 13% prevalence of nonalcoholic fatty liver disease. Because about 10% of people with nonalcoholic fatty liver disease are at risk for progressive fibrosis, the burden of this disease is now quite substantial. Incremental progress in understanding nonalcoholic fatty liver disease and nonalcoholic steatohepatitis promises to lead to new therapeutic options for this common disease.Keywords
This publication has 56 references indexed in Scilit:
- Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant miceProceedings of the National Academy of Sciences of the United States of America, 2006
- ER stress: Can the liver cope?Journal of Hepatology, 2006
- TelmisartanHypertension, 2006
- Telmisartan But Not Valsartan Increases Caloric Expenditure and Protects Against Weight Gain and Hepatic SteatosisHypertension, 2006
- Statin Safety: An Assessment Using an Administrative Claims DatabaseThe American Journal of Cardiology, 2006
- An Assessment of Statin Safety by HepatologistsThe American Journal of Cardiology, 2006
- Nonalcoholic Fatty Liver Disease Treated by GastroplastyDigestive Diseases and Sciences, 2006
- Decreased Insulin-Stimulated ATP Synthesis and Phosphate Transport in Muscle of Insulin-Resistant Offspring of Type 2 Diabetic ParentsPLoS Medicine, 2005
- Design and validation of a histological scoring system for nonalcoholic fatty liver diseaseHepatology, 2005
- Angiotensin II type 1 receptor blocker ameliorates overproduction and accumulation of triglyceride in the liver of Zucker fatty ratsAmerican Journal of Physiology-Endocrinology and Metabolism, 2004